These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 20880830)

  • 1. Thinking glutamatergically: changing concepts of schizophrenia based upon changing neurochemical models.
    Kantrowitz JT; Javitt DC
    Clin Schizophr Relat Psychoses; 2010 Oct; 4(3):189-200. PubMed ID: 20880830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions.
    Javitt DC
    Int Rev Neurobiol; 2007; 78():69-108. PubMed ID: 17349858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glutamatergic theories of schizophrenia.
    Javitt DC
    Isr J Psychiatry Relat Sci; 2010; 47(1):4-16. PubMed ID: 20686195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Has an angel shown the way? Etiological and therapeutic implications of the PCP/NMDA model of schizophrenia.
    Javitt DC; Zukin SR; Heresco-Levy U; Umbricht D
    Schizophr Bull; 2012 Sep; 38(5):958-66. PubMed ID: 22987851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phenomenology, aetiology and treatment of schizophrenia.
    Javitt DC
    Novartis Found Symp; 2008; 289():4-16; discussion 17-22, 87-93. PubMed ID: 18497092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Passing the torch: The ascendance of the glutamatergic synapse in the pathophysiology of schizophrenia.
    Coyle JT
    Biochem Pharmacol; 2024 Oct; 228():116376. PubMed ID: 38906225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Linking phencyclidine intoxication to the tryptophan-kynurenine pathway: Therapeutic implications for schizophrenia.
    Fujigaki H; Mouri A; Yamamoto Y; Nabeshima T; Saito K
    Neurochem Int; 2019 May; 125():1-6. PubMed ID: 30731185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glutamatergic (N-methyl-D-aspartate receptor) hypofrontality in schizophrenia: too little juice or a miswired brain?
    Marek GJ; Behl B; Bespalov AY; Gross G; Lee Y; Schoemaker H
    Mol Pharmacol; 2010 Mar; 77(3):317-26. PubMed ID: 19933774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Animal model of schizophrenia: dysfunction of NMDA receptor-signaling in mice following withdrawal from repeated administration of phencyclidine.
    Nabeshima T; Mouri A; Murai R; Noda Y
    Ann N Y Acad Sci; 2006 Nov; 1086():160-8. PubMed ID: 17185514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glutamatergic neurotransmission modulation and the mechanisms of antipsychotic atypicality.
    Heresco-Levy U
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 Oct; 27(7):1113-23. PubMed ID: 14642971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular mechanisms underlying glutamatergic dysfunction in schizophrenia: therapeutic implications.
    Gaspar PA; Bustamante ML; Silva H; Aboitiz F
    J Neurochem; 2009 Nov; 111(4):891-900. PubMed ID: 19686383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Glutaminergic hypothesis of schizophrenia: clinical research studies with ketamine].
    Mechri A; Saoud M; Khiari G; d'Amato T; Dalery J; Gaha L
    Encephale; 2001; 27(1):53-9. PubMed ID: 11294039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent advances in the phencyclidine model of schizophrenia.
    Javitt DC; Zukin SR
    Am J Psychiatry; 1991 Oct; 148(10):1301-8. PubMed ID: 1654746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Twenty-five years of glutamate in schizophrenia: are we there yet?
    Javitt DC
    Schizophr Bull; 2012 Sep; 38(5):911-3. PubMed ID: 22987849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phencyclidine animal models of schizophrenia: approaches from abnormality of glutamatergic neurotransmission and neurodevelopment.
    Mouri A; Noda Y; Enomoto T; Nabeshima T
    Neurochem Int; 2007; 51(2-4):173-84. PubMed ID: 17669558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alterations in glutamatergic signaling in the brain of dopamine supersensitivity psychosis and non-supersensitivity psychosis model rats.
    Oda Y; Fujita Y; Oishi K; Nakata Y; Takase M; Niitsu T; Kanahara N; Shirayama Y; Hashimoto K; Iyo M
    Psychopharmacology (Berl); 2017 Oct; 234(20):3027-3036. PubMed ID: 28744562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A revised excitotoxic hypothesis of schizophrenia: therapeutic implications.
    Deutsch SI; Rosse RB; Schwartz BL; Mastropaolo J
    Clin Neuropharmacol; 2001; 24(1):43-9. PubMed ID: 11290881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of the simultaneous enhancement of NMDA and dopamine D1 receptor-mediated neurotransmission in the effects of clozapine on phencyclidine-induced acute increases in glutamate levels in the rat medial prefrontal cortex.
    Abekawa T; Ito K; Koyama T
    Naunyn Schmiedebergs Arch Pharmacol; 2006 Dec; 374(3):177-93. PubMed ID: 17103144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Direct and indirect modulation of the N-methyl D-aspartate receptor.
    Marino MJ; Conn PJ
    Curr Drug Targets CNS Neurol Disord; 2002 Feb; 1(1):1-16. PubMed ID: 12769631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Central N-acetyl aspartylglutamate deficit: a possible pathogenesis of schizophrenia.
    Tsai SJ
    Med Sci Monit; 2005 Sep; 11(9):HY39-45. PubMed ID: 16127367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.